# Gasotransmitters bridging tumor biology and immunity: from pathophysiological insights to therapeutic potential

**Authors:** Giulia Ballerini, Andrea Balboni, Valentina Garlatti, Martina Incerti, Antonio Sica, Francesca Maria Consonni

PMC · DOI: 10.3389/fimmu.2026.1671203 · 2026-01-28

## TL;DR

This review explores how gas molecules like CO, NO, and H2S influence the tumor environment and immunity, offering insights into potential cancer therapies.

## Contribution

The paper provides a comprehensive overview of the dual roles of gasotransmitters in tumor biology and their therapeutic potential.

## Key findings

- Gasotransmitters modulate immune cell functions and tumor cell behavior in the tumor microenvironment.
- They influence redox balance, metabolism, and epigenetic regulation, affecting tumor progression and therapy resistance.
- Understanding these mechanisms could lead to novel strategies for reprogramming the tumor microenvironment.

## Abstract

The tumor microenvironment (TME) is a highly intricate and dynamic milieu, comprising neoplastic, immune and stromal cells in concert with extracellular matrix components, all engaged in continuous bidirectional crosstalk that critically orchestrates disease progression and therapeutic resistance. Beyond the local context, the TME is deeply shaped also by systemic influences, such as inflammatory mediators, metabolic cues and hematopoietic perturbations, collectively fostering a tumor-permissive macroenvironment. The interplay between local and systemic signals plays a pivotal role in modulating cellular differentiation, immune dynamics and stromal architecture, thereby sustaining malignancy. Among the myriad regulatory modulators involved in this complex network, endogenously produced gasotransmitters, namely carbon monoxide (CO), nitric oxide (NO) and hydrogen sulfide (H2S), have emerged as key modulators of tumor biology. These small, diffusible molecules exert a context-dependent spectrum of both pro-and anti-tumorigenic effects, influenced by their concentration, cellular source and tumor-specific microenvironmental conditions. Through the modulation of redox balance, metabolic signaling and epigenetic regulators, gasotransmitters impact immune cell functions, stromal remodeling and tumor cell behavior, thereby contributing to either immune evasion and therapy resistance or, conversely, to tumor suppression. Despite their growing relevance, the molecular mechanism governing these dualistic roles remain incompletely elucidated. This review provides a comprehensive overview of the current knowledge regarding the roles of CO, NO and H2S in shaping TME. We focus on their influence on immune, stromal and tumor cell differentiation, metabolism and function, and discuss how this understanding could inform novel therapeutic strategies aimed at reprogramming the TME to enhance clinical outcomes in cancer treatment.

## Linked entities

- **Chemicals:** carbon monoxide (PubChem CID 281), nitric oxide (PubChem CID 145068), hydrogen sulfide (PubChem CID 402)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, Nos1 (nitric oxide synthase 1, neuronal) [NCBI Gene 18125] {aka 2310005C01Rik, N-NOS, NC-NOS, NO, NOS, NOS-I}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Ctla4 (cytotoxic T-lymphocyte-associated protein 4) [NCBI Gene 12477] {aka Cd152, Ctla-4, Ly-56}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, ALOX12 (arachidonate 12-lipoxygenase, 12S type) [NCBI Gene 239] {aka 12-LOX, 12S-LOX, LOG12}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, Hif1a (hypoxia inducible factor 1, alpha subunit) [NCBI Gene 15251] {aka HIF-1-alpha, HIF1-alpha, HIF1alpha, MOP1, bHLHe78}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, CAT (catalase) [NCBI Gene 847], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, Nos3 (nitric oxide synthase 3, endothelial cell) [NCBI Gene 18127] {aka 2310065A03Rik, Nos-3, eNOS, ecNOS}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, VEGFC (vascular endothelial growth factor C) [NCBI Gene 7424] {aka Flt4-L, LMPH1D, LMPHM4, VRP}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, PRKG1 (protein kinase cGMP-dependent 1) [NCBI Gene 5592] {aka AAT8, PKG, PKG1, PRKG1B, PRKGR1B, cGK}, Ctnnb1 (catenin beta 1) [NCBI Gene 12387] {aka Bfc, Catnb, Mesc}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PTPA (protein phosphatase 2 phosphatase activator) [NCBI Gene 5524] {aka PARK25, PP2A, PPP2R4, PR53}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, PDE5A (phosphodiesterase 5A) [NCBI Gene 8654] {aka CGB-PDE, CN5A, PDE5}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, CHEK1 (checkpoint kinase 1) [NCBI Gene 1111] {aka CHK1, OZEMA21}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Cd274 (CD274 antigen) [NCBI Gene 60533] {aka A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1}, CBS (cystathionine beta-synthase) [NCBI Gene 875] {aka HIP4}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, MPST (mercaptopyruvate sulfurtransferase) [NCBI Gene 4357] {aka MST, TST2, TUM1}, NCR3 (natural cytotoxicity triggering receptor 3) [NCBI Gene 259197] {aka 1C7, CD337, LY117, MALS, NKp30}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, EPAS1 (endothelial PAS domain protein 1) [NCBI Gene 2034] {aka ECYT4, HIF2A, HLF, MOP2, PASD2, bHLHe73}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, Tnfsf10 (tumor necrosis factor (ligand) superfamily, member 10) [NCBI Gene 22035] {aka A330042I21Rik, APO-2L, Ly81, TL2, Tnlg6a, Trail}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, IFI27 (interferon alpha inducible protein 27) [NCBI Gene 3429] {aka FAM14D, ISG12, ISG12A, P27}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}
- **Diseases:** MDSCs (OMIM:601308), cytotoxic (MESH:D064420), immune dysfunction (MESH:D007154), colon cancer (MESH:D015179), tumorigenic (MESH:D002471), colon, ovarian and breast cancer (MESH:D061325), carcinogenic (MESH:D011230), lung metastasis (MESH:D009362), colorectal, breast, pancreatic and melanoma (MESH:C537262), brain tumors (MESH:D001932), invasive (MESH:D009361), glioblastoma (MESH:D005909), necrosis (MESH:D009336), ovarian sarcoma (MESH:D010049), hepatocellular carcinoma (MESH:D006528), cutaneous malignancies (MESH:C562393), colon and ovarian cancer (MESH:D010051), lymph node metastasis (MESH:D008207), basal-like breast cancer (MESH:D001943), TNBC (MESH:D064726), gastric injury (MESH:D013272), chronic kidney disease (MESH:D051436), epithelial tumor (MESH:D002277), gastrointestinal and oropharyngeal cancers (MESH:D009959), chronic myeloid leukemia (MESH:D015464), cancers (MESH:D009369), fibrosarcoma (MESH:D005354), A549 lung carcinoma (MESH:D008175), mitochondrial damage (MESH:D028361), pancreatic and hepatoma cancer (MESH:D010190), cervical cancer (MESH:D002583), hepatocellular and prostate cancer (MESH:D011471), glioma (MESH:D005910), melanoma (MESH:D008545), pancreatic ductal adenocarcinoma (MESH:D021441), PDAC (MESH:C537768), inflammation (MESH:D007249), medulloblastoma (MESH:D008527), colon carcinoma (MESH:D003110), Hypoxia (MESH:D000860), NSCLC (MESH:D002289), hematological malignancies (MESH:D019337), neuroblastoma (MESH:D009447), renal cancer (MESH:D007680), gastric cancer (MESH:D013274), lung adenocarcinoma (MESH:D000077192), hypoxic (MESH:D002534)
- **Chemicals:** S-propargyl-cysteine (MESH:C556437), DETA (MESH:D003671), L-Arginine (MESH:D001120), fatty acids (MESH:D005227), etoposide (MESH:D005047), FAD (MESH:D005182), pembrolizumab (MESH:C582435), NADPH (MESH:D009249), BH4 (MESH:C003402), amino acid (MESH:D000596), heme (MESH:D006418), homocysteine (MESH:D006710), GTN (MESH:D005996), ruthenium (MESH:D012428), doxorubicin (MESH:D004317), K+ (MESH:D011188), H2S (MESH:D006862), lopinavir (MESH:D061466), O3 (MESH:D010126), ADT (-), superoxide (MESH:D013481), cisplatin (MESH:D002945), calcium (MESH:D002118), ROS (MESH:D017382), glucose (MESH:D005947), AOAA (MESH:D000625), tin mesoporphyrin (MESH:C055421), H2 (MESH:D006859), GYY4137 (MESH:C529376), erucin (MESH:C073539), PLP (MESH:D011732), nivolumab (MESH:D000077594), Gas (MESH:D005708), gemcitabine (MESH:D000093542), diazeniumdiolates (MESH:C452539), durvalumab (MESH:C000613593), LPS (MESH:D008070), Cysteine (MESH:D003545), GSH (MESH:D005978), carboxy-PTIO (MESH:C079393), peroxynitrite (MESH:D030421), NaHS (MESH:C025451), FMN (MESH:D005486), nitroxyl (MESH:C039900), XELOX (MESH:C519688), ATP (MESH:D000255), PLX4032 (MESH:D000077484), biliverdin (MESH:D001664), DATS (MESH:C042577), paclitaxel (MESH:D017239), CO (MESH:D002248), bilirubin (MESH:D001663), Oxygen (MESH:D010100), sulphate (MESH:D013431), polysulfides (MESH:C032915), metal (MESH:D008670), Cyclic Guanosine Monophosphate (MESH:D006152), methimazole (MESH:D008713), NO (MESH:D009569), vinorelbine (MESH:D000077235)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), MMTV — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_KS75), B16 — Mus musculus (Mouse), Hybridoma (CVCL_U043), MC38 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_B288), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), MCF-7/ADR — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_1452), B16-F0 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0604), RAW264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493), B16-F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12895428/full.md

---
Source: https://tomesphere.com/paper/PMC12895428